Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference Business Wire - Mon May 11, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Business Wire - Tue May 5, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri May 1, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain Business Wire - Thu Apr 30, 3:05PM CDT

- The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Mar 13, 3:05PM CDT

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Business Wire - Thu Mar 5, 3:05PM CST

- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference Business Wire - Tue Mar 3, 3:05PM CST

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Feb 18, 3:05PM CST

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Wed Jan 28, 3:05PM CST

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering Business Wire - Thu Dec 11, 2025

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 13.65 (-6.06%)

Barchart Exclusives

Berkshire Hathaway Just Upped Its Stake in Sumitomo Stock. Greg Abel Says It’s Holding for the Long Term. Barchart - Mon May 11, 6:30PM CDT
Berkshire Hathaway has raised its stake in Sumitomo to 10.05% as of May 7, crossing the 10% threshold in all five major Japanese trading houses and signaling a long-term “permanent” holding under CEO Greg Abel. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.